During infection, the release of damage-associated molecular patterns, so-called "alarmins," orchestrates the immune response. The alarmin IL-33 plays a role in a wide range of pathologies. Upon release, IL-33 signals through its receptor ST2, which reportedly is expressed only on CD4 + T cells of the Th2 and regulatory subsets. Here we show that Th1 effector cells also express ST2 upon differentiation in vitro and in vivo during lymphocytic choriomeningitis virus (LCMV) infection. The expression of ST2 on Th1 cells was transient, in contrast to constitutive ST2 expression on Th2 cells, and marked highly activated effector cells. ST2 expression on virusspecific Th1 cells depended on the Th1-associated transcription factors T-bet and STAT4. ST2 deficiency resulted in a T-cell-intrinsic impairment of LCMV-specific Th1 effector responses in both mixed bone marrow-chimeric mice and adoptive cell transfer experiments. ST2-deficient virus-specific CD4 + T cells showed impaired expansion, Th1 effector differentiation, and antiviral cytokine production. Consequently, these cells mediated little virus-induced immunopathology. Thus, IL-33 acts as a critical and direct cofactor to drive antiviral Th1 effector cell activation, with implications for vaccination strategies and immunotherapeutic approaches.
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IL-33 | ST2 | CD4 T cell | Th1 cell | virus infection I ntercellular signaling molecules, such as cytokines and damageassociated molecular patterns (DAMPs), are essential for the induction and amplification of immune responses. DAMPs are multifunctional host proteins that indicate tissue damage. They are also referred to as alarmins, because they serve as early warning signals to activate innate and adaptive immune responses (1) . The alarmin IL-33, a member of the IL-1 family, is constitutively expressed in the nucleus of endothelial and epithelial cells and is released during tissue damage and necrosis (2) . Upon release, IL-33 mediates its activity through a heterodimeric cell surface receptor consisting of the ubiquitous IL-1R accessory protein (IL1RAcP) and the more selectively expressed receptor ST2, also known as T1 and IL-1RL1 (3, 4) . The intracellular signaling pathway of this receptor complex includes the recruitment of MyD88 and leads to the activation of NF-κB, ERK, p38, and JNK pathways (2) . IL-33 acts on a wide range of immune cells, but has been implicated predominantly in Th2-associated immune responses (5) . Nonetheless, this categorization has recently been challenged by reports describing IL-33 as an enhancer of IFN-γ production by iNKT cells, NK cells, and CD8 + T cells (6) (7) (8) . In addition, IL-33 signaling is important for the activation and functionality of cytotoxic CD8 + T cells during viral infection (9) .
In the present work, we studied a potential impact of IL-33 on Th1 cell responses in vitro and in vivo. In the course of infection with LCMV, which potently induces Th1-differentiated effector CD4 + T cells (10) , we found that many of the virus-specific CD4 + T cells expressed the IL-33 receptor ST2. ST2 expression marked activated effector Th1 cells and differed in terms of intensity and stability from the previously described ST2 expression of Th2 cells. At the molecular level, the Th1-associated transcription factors T-bet and STAT4 controlled ST2 expression in vivo and in vitro. ST2 deficiency of LCMVspecific CD4 + T cells resulted in impaired effector Th1 cell differentiation with substantially reduced cell expansion, impaired antiviral cytokine production, and little virus-induced T-cell-mediated immunopathology. Thus, IL-33 acts directly on CD4 + T cells during infection to enhance antiviral effector Th1 cell responses.
Results
Transient ST2 Expression on Virus-Specific CD4 + T Cells Is Associated with Enhanced Th1 Effector Properties. We set out to investigate whether CD4 + effector T cells can express ST2 during a Th1promoting infection. To do so, we analyzed endogenous CD4 + T cells in LCMV-infected WT mice, as well as adoptively transferred LCMV-TCR transgenic (tg) CD4 + T cells with a congenic marker (Thy1.1 + ). Given that regulatory T cells (Tregs) are known to express ST2 (11), we excluded CD4 + FoxP3 + T cells from our flow cytometry analysis. Endogenous CD4 + effectors were defined by their down-regulation of CD62L and showed transient expression of ST2 that peaked at day 8 postinfection ( Fig. 1 A and B) . The analysis of CD4 + T cells at the peak of ST2 expression confirmed that ST2 was expressed exclusively on activated CD62L lo CD4 + T cells, and not on resting CD62L hi CD4 + T cells (Fig. 1C ). Transient ST2 expression
Significance
The alarmin IL-33 amplifies immune responses of Th2 and CD8 + cytotoxic T cells against invading pathogens; however, little is known about a potential role of IL-33 in Th1 cell responses. This study demonstrates that activated Th1 effector cells transiently express the IL-33 receptor ST2 upon differentiation in vitro and in vivo during viral infection. ST2 expression on virus-specific Th1 cells depended on the Th1-associated transcription factors T-bet and STAT4. ST2-deficient virus-specific CD4 + T cells showed impaired expansion and Th1 effector function upon viral infection, indicating a direct impact of IL-33 on antiviral Th1 cell responses. These observations redefine the role of ST2 in Th cell activation, with implications for the design of adjuvants and therapies targeting the IL-33-ST2 pathway.
during LCMV infection was found on transferred LCMV-TCR tg CD4 + T cells as well ( Fig. 1D ). Here the peak of ST2 expression was observed at day 6 postinfection, followed by a gradual decrease until day 14.
To characterize ST2 + CD4 + T cells during virus-induced Th1 differentiation, we analyzed endogenous CD4 + T cells in WT mice at the peak of ST2 expression on day 8 postinfection (cf. Fig. 1B ). At this time point, the majority of ST2 + CD4 + T cells were CD62L lo CD44 + effector cells (Fig. 1E ). In addition, we found several functional differences between ST2 + and ST2 − effector CD4 + T cells. The ratio between IFN-γ producers and nonproducers was higher within the ST2 + CD44 + CD4 + T cells (Fig. 1F ). The lineage-specifying transcription factor of Th1 cells, T-bet (12) , was preferentially expressed within the ST2 + fraction of effector CD4 + T cells, just like the Th1-associated receptors CXCR3 (13) and IL-18R (14) ( Fig. 1 G and H) . In contrast, the expression of GATA-3, FoxP3, and Eomesodermin did not differ substantially between ST2 + and ST2 − effector CD4 + T cells ( Fig.  S1 ). Taken together, these data indicate that Th1 cells transiently express the IL-33 receptor ST2 at the peak of LCMV infection, and that the ST2 + fraction of the CD4 + T cells is highly activated and exhibits enhanced Th1 effector properties.
ST2 Expression Is Weaker and Less Stable on Th1 Cells than on Th2
Cells. Having detected ST2 on effector Th1 cells in vivo, we next examined whether in vitro-generated Th1 cells also express ST2. After two rounds of in vitro differentiation, we found ST2 protein on both Th1 and Th2 cells ( Fig. 2A ). The frequency of ST2 + cells was comparable in the two subsets ( Fig. 2B ), whereas the amounts of ST2 protein ( Fig. 2C ) and Il1rl1 mRNA ( Fig. 2D ) were clearly higher in Th2 cells than in Th1 cells. Both subsets expressed homogenously and exclusively their lineage-specifying transcription factors T-bet (Th1) and GATA-3 (Th2), and did not express the Treg transcription factor FoxP3 ( Fig. 2E ). ST2 receptor signaling was functional in Th1 cells, as demonstrated by the finding that exposure to IL-33 increased phospho-p38 levels ( Fig. S2) .
To determine the stability of ST2 expression, we further cultured Th1 and Th2 cells under resting conditions with IL-7 but in the absence of polarizing cytokines. ST2 expression on Th1 cells decreased within the first 24 h and continuously thereafter ( 2F). In contrast, Th2 cells maintained and even slightly increased their ST2 expression ( Fig. 2G ). Th1 cells maintained their differentiated phenotype while losing ST2 expression ( Fig. 2H and Fig. S3 ). Importantly, when Th1 cells were sorted into ST2 + and ST2 − subpopulations and plated separately, the survival of the two subsets in culture was indistinguishable ( Fig. 2I ), making it unlikely that preferential cell death of ST2 + Th1 cells had confounded the analysis of ST2 down-regulation. Thus, in vitrogenerated Th1 cells can express ST2, which is down-regulated by these cells during resting conditions.
T-bet and STAT4 Regulate ST2 Expression on Th1 cells in Vivo and in
Vitro. Ectopic GATA-3 expression experiments and studies on inducible GATA-3-deficient cells have shown that ST2 expression in Th2 and Treg cells is dependent on GATA-3 (15, 16) . In contrast, ST2 + Th1 cells did not express elevated GATA-3 levels, and their expression pattern of ST2 differed from that of Th2 cells (Fig. 2) . Thus, we hypothesized that other transcriptional regulators are essential to Th1-associated ST2 expression. STAT4 and T-bet are both crucial in Th1 differentiation (12, 17) . When adoptively transferred into WT recipients, T-bet-deficient (Tbx21 −/− ) and STAT4-deficient (Stat4 −/− ) LCMV-TCR tg effector CD4 + T cells exhibited impaired ST2 expression on days 6-10 after LCMV infection (Fig. 3A) . In contrast, IFN-γR signals were dispensable for ST2 expression, as demonstrated by the finding that IFN-γR-deficient (Ifngr1 −/− ) LCMV-TCR tg CD4 + Thy1.1 + cells exhibited normal ST2 levels when tested analogously ( Fig. S4 ).
Based on impaired ST2 expression in vivo, we also analyzed in vitro-differentiated Tbx21 −/− and Stat4 −/− Th1 cells. Despite their respective genetic defects, differentiation of both genotypes resulted in activated cells with clear Th1 characteristics ( Fig. S5 ). Control Th1 cells expressed T-bet as expected and showed increased ST2 expression throughout the second round of differentiation ( Fig. 3B ). Tbx21 −/− Th1 cells phosphorylated STAT4 but displayed impaired ST2 expression ( Fig. 3C) . Similarly, Stat4 −/− Th1 cells failed to express ST2 despite enhanced T-bet expression early in the second round of differentiation ( Fig. 3D ). IL-2 can contribute to ST2 expression in Th2 cells in a STAT5-dependent fashion (15) , but it failed to rescue ST2 in Tbx21 −/− and Stat4 −/− Th1 cells ( Fig. S6 ). These findings suggest that both T-bet and STAT4 are required for optimal ST2 expression in Th1 cells.
ST2-deficient CD4 + T Cells Are Impaired in Expansion and Cytokine
Production After Viral Infection. IL-33 is released to the extracellular space during infection, thereby acting as an alarmin that should be accessible to differentiating ST2 + Th1 cells. Indeed, Il1rl1 −/− mice generated fewer cytokine-producing CD4 + T cells than WT controls ( Fig. 4A ), which was evident in both the percentage and absolute number of CD4 + T cells expressing IFN-γ, TNF-α, IL-2, and combinations thereof ( Fig. S7 A and B) .
To directly address the CD4 + T-cell-intrinsic role of ST2 in the antiviral response, we reconstituted lethally irradiated WT mice with WT and Il1rl1 −/− bone marrow. In the resulting chimeras, Il1rl1 −/− CD4 + T cells were slightly more abundant than WT CD4 + T cells (differentiated by the CD45.1 congenic marker) in both the naive CD44 lo compartment and the effector/ memory (CD44 hi ) pool ( Fig. 4B and Fig. S7C ). This finding indicates that IL-33 signals are not required for homeostatic maintenance of either CD4 + T-cell compartment. At day 9 after the LCMV challenge, however, WT CD44 hi CD4 + T cells outnumbered CD44 hi Il1rl1 −/− CD4 + T cells by approximately fourfold (Fig. 4B ). Conversely, both CD44 lo compartments contracted proportionally ( Fig. 4B and Fig. S7C ). In concert with these observations, LCMV GP66-77 MHC class II tetramerbinding cells were significantly more frequent within the WT CD4 + T-cell compartment than within the Il1rl1 −/− CD4 + T-cell compartment, and were virtually uniformly CD44 hi cells ( Restimulation with an immunodominant LCMV-derived peptide epitope revealed that cytokine-expressing cells were significantly less frequent within the Il1rl1 −/− CD4 + T-cell compartment than within the WT CD4 + T-cell compartment (Fig. 4E ). These differences were evident at the level of absolute effector CD4 + T-cell counts as well ( Fig. S7D ). Furthermore, we noted that IFN-γ expression levels in Il1rl1 −/− CD4 + T cells were modestly yet consistently diminished ( Fig. 4F ). Thus, IL-33 signals serve critical cell-intrinsic functions in polyfunctional CD4 + T-cell responses to viral infection.
Adoptively Transferred ST2-deficient CD4 + T Cells Cause Less Virus-Induced Immunopathology. Impaired antiviral CD4 + T-cell responses, as observed in Il1rl1 −/− mice and mixed bone marrowchimeric mice, are suggestive of an intrinsically defective Th1 differentiation of Il1rl1 −/− CD4 + T cells. Independent support for this concept stemmed from Th1 polarization experiments, which were conducted with limiting IL-12 concentrations. In this setting, Il1rl1 −/− CD4 + T cells exhibited lower T-bet, IFN-γ, CD44, and IL-18R expression compared with Il1rl1 +/+ control cells ( Fig. S8) .
To address the functional impact of this finding, we exploited the LCMV wasting disease model, in which effector CD4 + T cells can mediate weight loss (18, 19) . We adoptively transferred Il1rl1 +/+ or Il1rl1 −/− LCMV-TCR tg CD4 + Thy1.1 + cells into WT mice and monitored their body weight after LCMV infection. Recipients of Il1rl1 +/+ LCMV-TCR tg CD4 + Thy1.1 + cells lost significantly more weight than recipients of Il1rl1 −/− LCMV-TCR tg CD4 + Thy1.1 + cells (Fig. 5A) . Analysis of the transferred cells at day 6 postinfection demonstrated lower cell numbers and reduced T-bet expression by the Il1rl1 −/− CD4 + Thy1.1 + cells ( Fig. 5 B and C) . Furthermore, cytokine expression by the transferred CD4 + Thy1.1 + cells was diminished in the Il1rl1 −/− fraction ( Fig. 5D and Fig. S9 ). The Il1rl1 −/− CD4 + T cells also displayed reduced expression of CXCR3 and CD44 ( Fig. 5 E and F) , indicating diminished potential to migrate to inflamed sites of infection and impaired activation, respectively. The endogenous CD8 + T-cell response did not differ between the recipients of Il1rl1 +/+ and Il1rl1 −/− CD4 + T cells, as demonstrated by a similar frequency of LCMV-specific GP33 tetramer-positive CD8 + T cells and similar CD44 expression by these cells (Fig. 5 G and H) . These findings indicate that the impaired expansion, activation, and effector differentiation of Il1rl1 −/− CD4 + T cells result in a decreased immunopathological potential after LCMV infection.
Discussion
In this study, we have shown that the IL-33 receptor ST2 is induced on Th1 effector cells upon differentiation in vitro and in vivo during LCMV infection. ST2 expression on Th1 cells is transient and is associated with the cellular activation status. In Th1 cells, STAT4 and T-bet cooperate to drive ST2 expression. The absence of ST2 on CD4 + T cells impairs Th1 cell activation during viral infection and results in decreased expansion, impaired effector function, and reduced T-cell-mediated immunopathology.
ST2 protein has been reported to be expressed on in vitrodifferentiated Th2 but not Th1 cells (20) . In addition, ST2 + CD4 + T cells isolated from uninfected mice display mostly Th2 characteristics, such as expression of IL-4 and IL-5 (21) . Using improved detection methods, we now show that ST2 is also expressed on activated Th1 cells, albeit at a lower expression level. Moreover, Th1 cells intrinsically down-regulate ST2 expression when transferred to resting conditions. Comparably higher stability and intensity of ST2 expression on Th2 cells may explain why in earlier ex vivo isolations from uninfected mice, ST2 + CD4 + T cells exhibited mainly Th2 cell characteristics (21) . Very likely, Th1 cells originating from previous infections of those mice had lost ST2 expression while transitioning to a resting state, precluding detection of the ST2 receptor on these cells. The lineage decision of Th cell subsets is controlled by "master regulator" transcription factors, e.g., T-bet in Th1 (12) and GATA-3 in Th2 cells (22) . Nonetheless, T-bet and GATA-3 also share a considerable set of target genes (23) . GATA-3 has been identified as an inducer of ST2 expression in Th2 and Treg cells (15, 16) . In contrast to Th2 cells, Th1 cells express only very low levels of GATA-3 and show a transient ST2 expression pattern; therefore, transcription factors other than GATA-3 likely play a role in Th1-related ST2 expression.
Indeed, we identified both T-bet and STAT4 as key drivers of ST2 expression in Th1 cells in vitro and in vivo during LCMV infection. This finding is in line with transcription factor-binding data from ChIP-Seq experiments with in vitro-differentiated Th1 cells indicating the binding of T-bet (24) and STAT4 (25) to the ST2 gene locus. Thus, the induction of ST2 expression may be accomplished by direct activation of Il1rl1 enhancers and promoters and/or permissive epigenetic changes by T-bet and STAT4.
ST2 expression on CD4 + T cells coincides with increases in splenic IL-33 mRNA during viral infection (9) , suggesting an impact of IL-33 on effector CD4 + T-cell differentiation. This notion is supported by several results. First, the ST2 + fraction of the Th1 effector cells exhibited more pronounced Th1 cell characteristics and increased cell activation compared with their ST2 − counterparts at the peak of LCMV infection. Second, in WT and Il1rl1 −/− mixed bone marrow chimeras, IL-33 signals were critical for the expansion and antiviral cytokine production of CD4 + T cells in LCMV infection. Finally, adoptively transferred LCMV-specific Il1rl1 −/− CD4 + T cells showed decreased expansion, activation, and Th1 cell differentiation at the peak of LCMV infection, which translated into a reduced immunopathological potential of these cells.
Il1rl1 −/− CD4 + T cells exhibited decreased activation and Th1 effector characteristics during LCMV infection, but Th1 cell differentiation per se was not completely abrogated. This finding is in line with the function of IL-33 as a general alarmin and not as a Th1-specific factor. This is reflected by the plethora of different target cells of IL-33 (5) and the downstream signaling of its receptor, leading to the activation of rather broad transcriptional regulators like JNK, NF-κB, and p38 MAPK (2) . Nevertheless, an impact of two of those factors on optimal Th1 effector differentiation has already been documented. NF-κB plays a T-cell-intrinsic role in optimizing Th1 cell differentiation (26) , and the p38 MAP kinase pathway is required for optimal expression of IFN-γ in effector Th1 cells (27) .
Taken together, our data indicate a direct and enhancing activity of the alarmin IL-33 on virus-induced effector Th1 cells. These findings have considerable implications for the design of therapies that include the application of IL-33 or the blockade of its receptor ST2. Primary T-Cell Cultures. Naive CD4 + CD62L hi CD44 − cells were sorted from pooled spleen and lymph node cells by FACS. T cells were cultured as described in SI Materials and Methods.
Materials and Methods
Flow Cytometry Analysis. Flow cytometry detection of cell surface ST2 was done after a two-step amplification procedure, increasing fluorescence intensity, as described previously (9) . Further stainings are described in SI Materials and Methods.
Statistical Analysis. Unless stated otherwise, two-way ANOVA was used for multiple comparisons, and the unpaired two-tailed Student t test was used for comparisons of two groups (GraphPad Prism 5.02). *P = 0.01-0.05, statistically significant; **P = 0.001-0.01, very significant; ***P < 0.001, extremely significant. 
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SI Materials and Methods
Mice. Il1rl1 −/− , Tbx21 −/− , Stat4 −/− , and Ifngr1 −/− mice were bred on a C57BL/6 background. SMARTA1 TCR-tg mice, which express a TCR specific for the LCMV glycoprotein epitope GP61-80, were crossed to Thy1.1 + B6.PL, Il1rl1 −/− , Tbx21 −/− , Stat4 −/− , and Ifngr1 −/− mice to generate TCR tg mice on the respective mutant backgrounds.
Bone Marrow Chimeras and Adoptive Cell Transfer. WT recipients (CD45.1 + ) of bone marrow (1.5 × 10 7 cells each of WT CD45.1 + and Il1rl1 −/− CD45.2 + ) were lethally irradiated (11 Gy in two doses given 6 h apart) at 1 d before hematopoietic reconstitution, and residual T cells were depleted on the day of reconstitution (100 μg T24 anti-Thy1 antibody i.p.). Recipients were rested for ∼ 3 mo for hematopoietic reconstitution before the LCMV challenge was conducted. CD4 + T cells of Thy1.1 + SMARTA1 TCR-tg mice of the respective knockout backgrounds (6-8 wk old) were purified by staining with biotinylated antibodies against CD8 (53-6.7), CD11c (N418), CD11b (M1/70), CD19 (1D3), NK1.1 (PK136), Gr1 (RB6-8C5), CD25 (7D4), CXCR3 (CXCR3-173), and ST2 (DJ8), followed by antibiotin microbeads and magnetic depletion (Miltenyi Biotec). For each recipient, 2 × 10 5 cells of the biotin-negative fraction were transferred i.v.
Primary T-Cell Cultures. Naive CD4 + CD62L hi CD44 − cells were sorted from pooled spleen and lymph node cells by FACS. Unless stated differently, T cells were cultured in RPMI 1640 + GlutaMax-I supplemented with 10% (vol/vol) FCS (Gibco; Life Technologies), penicillin (100 U/mL; Gibco; Life Technologies), streptomycin (100 μg/mL; Gibco; Life Technologies), and β-mercaptoethanol (50 ng/mL; Sigma-Aldrich) in the presence of antigen-presenting cells and 1 μg/mL GP64 (LCMV-GP 64-80 ). For Th1 differentiation, 5 ng/mL IL-12, 5 ng/mL IL-2, and 10 μg/mL anti-IL-4 (11B11) were added. For Th2 differentiation, 10 ng/mL IL-4, 5 ng/mL IL-2, 10 μg/mL anti-IL-12 (C17.8), and 10 μg/mL anti-IFN-γ (AN18.17.24) were added. On day 4, cells were reactivated with fresh antigen-presenting cells plus 1 μg/mL GP64, and cytokines and blocking cytokine antibodies as above. For resting conditions, cells were cultured at day 8 in fresh medium with 1 ng/mL IL-7 for 5 more days. Recombinant cytokines were purchased from R&D Systems, Peprotech, and Miltenyi Biotec. At the indicated analysis time point, cells were purified with Histopaque (Sigma-Aldrich) and high-density centrifugation (400 × g at 20°C for 20 min).
Flow Cytometry Analysis. Surface receptor staining and intracellular cytokine, transcription factor, and pSTAT4 staining procedures have been described previously (1) . The LCMV-specific CD8 + T-cell response to the dominant glycoprotein-derived epitope GP33 was assessed by MHC class I tetramer staining as described previously (2) . The LCMV-specific CD4 + T-cell response was assessed by MHC class II tetramer staining. For these analyses, phycoerythrin-conjugated I-Ab MHC class II tetramer complexes loaded with either the LCMV glycoprotein aa66-77 epitope DIYKGVYQFKSV or the human CLIP-derived aa87-101 epitope PVSKMRMATPLLMQA were generously provided by the US National Institutes of Health's Tetramer Facility.
For intracellular staining of p38 protein phosphorylation, cells were starved for 4 h in serum-free medium and treated with or without IL-33 (30 ng/mL) for another 30 min. Cells were subsequently fixed with prewarmed 1× BD Phosflow Lyse/Fix Buffer for 10 min at 37°C. Cells were permeabilized with ice-cold BD Phosflow Perm Buffer III for 30 min on ice, then stained for 30 min with PE anti-phospho-p38 (36/p38, BD Biosciences). Additional FACS analysis, not described before, included surface marker stainings for Ly6C (AL-21; BD Biosciences) and CCR6 (140706; R&D Systems), intracellular staining of IL-17A (TC11-18H10.1; Biolegend) after restimulation with PMA and ionomycin, and intracellular transcription factor staining of FoxP3 (FJK-16s; eBioscience) and RORγt (Q31-378; BD Biosciences).
Gene Expression Analysis. mRNA of in vitro-generated Th cells was isolated with the NucleoSpin RNA II Kit (Macherey Nagel) according to the manufacturer's instructions. cDNA was prepared with TaqMan reverse-transcription reagents and quantified with SYBR Select (both from Applied Biosystems). Il1rl1 (forward, CAAGTAGGACCTGTGTGCCC; reverse, CGTGT-CCAACAATTGACCTG) was normalized to Hprt (forward, TCCTCCTCAGACCGCTTTT; reverse, CATAACCTGGTT-CATCATCGC).
Virus. The LCMV-WE strain was propagated on L-929 cells. LCMV stocks were titrated by standard immunofocus assays on MC57G cells as described previously (3) . Mice were infected i.v. with 200 or 2 × 10 6 PFU in 200 μL of MEM. 
